| Objective: Combined with the curative effect of the ancient Prescription HeidiHuangwan in treating chronic renal failure to evaluate its value of pharmacoeconomics, and toprovide an objective basis for clinical application and to spread and apply the cost benefitanalysis in clinic. Methods: Adopt the method of randomized, prospective, parallelpositive drug control and observe100eases of the CRF patients, who are randomly dividedinto50treatment group that take HeidiHuang wan, with50another group taking ShenshuaiNing for2months. There is one drop out of the control group. Statistics the clinicalsymptoms integral, the renal function, and the benefit of two groups before and aftertreatment. To undertake the cost-benefit analysis. Results:1. The total efficiency of the testgroup is92.0%,which is significantly better than the control group85.7%,(p＜0.05).2. Twodrugs can decline the clinical symptoms integral of the chronic renal failure, and there wassignificant difference compared with the control group,(p<0.01).3.The net benefit andbenefit-cost tatio of the test group is higher than the control group.3. There are no adversereaetions during the treatment. Conclusion: HeidiHuang wan is effective, economicaland safe to treat the chronic renal failure on the premise of the limited medical and healthresources. It is worth popularization and application. |
PDF Full Text Request